| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000019634 |
| P698 | PubMed publication ID | 9643663 |
| P2093 | author name string | Tyrrell CJ | |
| Iversen P | |||
| Anderson JB | |||
| Webster A | |||
| Chamberlain M | |||
| Baert L | |||
| Blackledge G | |||
| Kaisary AV | |||
| Tammela T | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bicalutamide | Q1988832 |
| P304 | page(s) | 447-456 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | European Urology | Q15763991 |
| P1476 | title | A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer | |
| P478 | volume | 33 |
| Q34145167 | An evaluation of bicalutamide in the treatment of prostate cancer |
| Q85232838 | An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study |
| Q38568568 | Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer |
| Q43570313 | Androgen antagonists: Potential role in prostate cancer prevention |
| Q46755042 | Androgen deprivation for advanced prostate cancer |
| Q34335616 | Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy |
| Q34960686 | Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks |
| Q35881896 | Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? |
| Q38016530 | Androgen deprivation therapy: past, present and future |
| Q42870883 | Androgen-Deprivation Therapy in Prostate Cancer: Clinical Evidence and Future Perspectives |
| Q57693897 | Anti-androgen monotherapy for metastatic prostate cancer |
| Q37148218 | Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling |
| Q37606741 | Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target |
| Q34086664 | Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer |
| Q34856651 | Antiandrogen monotherapy: indications and results |
| Q33832646 | Antiandrogens in prostate cancer |
| Q46936634 | Apples and oranges. Re: 7.4-year update of the ongoing bicalutamide Early Prostate Cancer (EPC) trial programme |
| Q34293191 | Bicalutamide (Casodex) in the treatment of prostate cancer |
| Q28377852 | Bicalutamide (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins |
| Q33604137 | Bicalutamide dosages used in the treatment of prostate cancer |
| Q74600046 | Bicalutamide in advanced prostate cancer. A review |
| Q34143921 | Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health‐related quality of life benefits for osteoporotic men with prostate cancer |
| Q44214494 | Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial. |
| Q33982691 | Bicalutamide: clinical pharmacokinetics and metabolism |
| Q35215084 | Biochemical recurrence of prostate cancer |
| Q38326753 | Chemical castration and anti-androgens induce differential gene expression in prostate cancer. |
| Q41734683 | Choice of hormonal therapy for prostate cancer |
| Q34348302 | Clinical conduct and nursing quality of life in prostate cancer |
| Q34348296 | Complementary and alternative therapies for advanced prostate cancer |
| Q34211155 | Contemporary role of androgen deprivation therapy for prostate cancer |
| Q34938317 | Controversies in the systemic management of patients with evidence of biochemical failure following radical prostatectomy |
| Q44297420 | Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer |
| Q38803264 | Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. |
| Q35160796 | Development of β-amino-carbonyl compounds as androgen receptor antagonists. |
| Q37000514 | Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. |
| Q48968382 | Effects of surgical and chemical castration on spatial learning ability in relation to cell proliferation and apoptosis in hippocampus |
| Q39756960 | Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer |
| Q34415540 | Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study |
| Q34339501 | Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer |
| Q36173646 | Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer |
| Q44499095 | Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up |
| Q36710251 | Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a European perspective |
| Q38324695 | Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate. |
| Q35041311 | Health related quality of life in prostate carcinoma patients: a systematic review of randomized controlled trials |
| Q35071335 | Health-related quality-of-life assessments in patients with advanced cancer of the prostate |
| Q37204444 | Hormonal approaches in prostate cancer: application in the contemporary prostate cancer patient |
| Q35569303 | Hormonal therapy in metastatic prostate cancer: current perspectives and controversies |
| Q84392078 | Hormonal therapy of prostate cancer |
| Q35640636 | Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer |
| Q36023678 | Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy |
| Q27015904 | Hormone naïve prostate cancer: predicting and maximizing response intervals |
| Q33913161 | Hormone therapy of prostate cancer: is there a role for antiandrogen monotherapy? |
| Q79292981 | Immediate dual energy X‐ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation |
| Q51786275 | Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter? |
| Q40377690 | Interaction of beta-catenin and TIF2/GRIP1 in transcriptional activation by the androgen receptor |
| Q45795876 | Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial |
| Q44606031 | Is Bicalutamide Equivalent to Goserelin for Prostate Volume Reduction before Radiation Therapy? A Prospective, Observational Study |
| Q78704183 | Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? |
| Q38050466 | Landmarks in hormonal therapy for prostate cancer |
| Q44597208 | Long‐term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12‐year results of a phase II study |
| Q44466090 | Management of treatment-related osteoporosis in men with prostate cancer |
| Q85937422 | Management options for gynaecomastia and breast pain associated with nonsteroidal antiandrogen therapy : case report series |
| Q36456480 | Managing complications of androgen deprivation therapy for prostate cancer |
| Q33938053 | Non-steroidal anti-androgens in prostate cancer--current treatment practice |
| Q24193722 | Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer |
| Q34454697 | Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review |
| Q28140656 | Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function |
| Q34856701 | Osteoporosis during androgen deprivation therapy for prostate cancer |
| Q34145785 | Patient-Clinician choice in palliation of metastatic prostate cancer |
| Q51840218 | Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging. |
| Q36573874 | Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments |
| Q93031961 | Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study |
| Q80075180 | Preliminary results of bicalutamide monotherapy on biochemical failure of localized prostate cancer |
| Q34804009 | Prostate cancer and health-related quality of life: a review of the literature. |
| Q81640912 | Prostate cancer in the elderly |
| Q27022847 | Prostate cancer: ESMO Consensus Conference Guidelines 2012 |
| Q35053929 | Prostate carcinoma: defining therapeutic objectives and improving overall outcomes |
| Q36516491 | Quality of life assessment in surgical oncology trials |
| Q73948778 | Quality of life in patients with prostate cancer |
| Q38986405 | Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer |
| Q35609554 | Recurrent prostate cancer following external beam radiotherapy: follow-up strategies and management |
| Q36395149 | Rising prostate-specific antigen after primary prostate cancer therapy |
| Q41189502 | Risk of thromboembolic disease in men with prostate cancer undergoing androgen deprivation therapy |
| Q35076189 | Risk stratification in the hormonal treatment of patients with prostate cancer |
| Q37018960 | Role of 5 alpha-reductase inhibitors in the management of prostate cancer |
| Q34441134 | Safety of antiandrogen therapy for treating prostate cancer |
| Q36335068 | Side-effects of treatments for locally advanced prostate cancer |
| Q46407820 | Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer |
| Q35059214 | The course of metastatic prostate cancer under treatment |
| Q37678989 | The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. |
| Q33962011 | The management of prostate cancer in patients with a rising prostate-specific antigen level |
| Q44447358 | The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study |
| Q35211251 | The timing of hormone therapy for men with asymptomatic advanced prostate cancer |
| Q57407578 | Tolerability of Antiandrogens in the Treatment of Prostate Cancer |
| Q34537714 | Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration |
| Q95512677 | Treating prostate cancer in elderly men: how does aging affect the outcome? |
| Q34105531 | Treatment options after failure of local curative treatments in prostate cancer: a controversial issue |
| Q31962923 | Treatment options for early prostate cancer |
| Q50789308 | Urology Update from Jackson Hole: Highlights from the 3rd Annual Jackson Hole Summer Urologic Conference July 28-August 3, 2001, Jackson Hole, WY. |
| Q35047981 | Value of endocrine therapy for early and locally advanced prostate cancer |
| Q35211260 | Variables in predicting survival based on treating "PSA-only" relapse |
| Q34555460 | What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care? |
| Q45233216 | Which patients with prostate cancer are actually candidates for hormone therapy? |
| Q40614054 | Will the experience with tamoxifen in breast cancer help define the role of antiandrogens in prostate cancer? |
| Q79956708 | [The treatments of localized prostate cancer: the impact on sexuality] |
| Q50773568 | [Update of the treatment of advanced prostate cancer and management of its complications]. |
Search more.